

PHARMANUTRA: REVENUES FOR THE FIRST HALF OF 2018 UP BY 20%. THE GROUP STRENGTHENS ITS INTERNATIONAL PRESENCE

Pisa, 26 July 2018 - PharmaNutra (Aim Italia - Ticker PHN), a leading nutraceutical company in the dietary iron supplements sector, announces the preliminary consolidated revenue figures for the first half of 2018 (not yet audited). The overall results will be announced after the Board of Directors' meeting to approve the interim financial report on 25 September 2018.

Revenues for the first half of 2018

In the first half of the year, the PharmaNutra Group recorded consolidated revenues of 22.1 million Euros, up by approximately 20% on the same period last year. The increase is the result of the consolidation of operations on Italian and foreign markets. Specifically, the Group strengthened its international presence considerably, which was supported by success in research and development activities. The Group performed excellently in the Italian market thanks to the successful launch of the new UltraMag® brand, accompanied by the growth in the network of sales representatives.

Roberto Lacorte, Vice Chairman of PharmaNutra, said: *"This has been an intense year, marked by great satisfaction from investor relations and the performance of the stock market. As anticipated at the beginning of the year, we want to share these outstanding results with our investors. These figures point to double-digit growth which reflects the ongoing development of the Group's business".*

PharmaNutra S.p.A.

Founded and guided by General Director Andrea Lacorte and Managing Director Roberto Lacorte, PharmaNutra was established in 2003 that develops unique nutraceutical supplements and innovative nutritional devices, taking care of the entire production process, from the proprietary raw materials to the finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 79 of them published with more than 5000 patients treated. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

<http://www.PharmaNutra.it>



For information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
Fax +39 050 7846524
investorrelation@pharmanutra.it

Nomad & Specialist

CFO SIM S.p.A.
Via dell'Annunciata 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication&Partners

Tel. +39 02 83635708
Matteo Russo - Cristina Tronconi
Mob. +39 347 9834881 +39 346 0477901
mrusso@sprianocommunication.com
ctronconi@sprianocommunication.com